“…The single nucleotide polymorphisms (SNPs) of PTPN22 , predominantly p.Arg620Trp (c.1858C>T), are among the major causative agents of human autoimmune disorders. Associations of PTPN22 SNPs with type 1 diabetes (T1DM) [3,4,5], latent autoimmune diabetes in adults (LADA) [6,7], autoimmune thyroid diseases (including Graves' disease and Hashimoto's thyroiditis) [8,9,10], rheumatoid arthritis (including anticitrullinated peptide antibody-negative subjects) [11], juvenile idiopathic arthritis [12], systemic lupus erythematosus [13,14,15], thymoma-associated myasthenia gravis [16], antineutrophil cytoplasmic autoantibodies (ANCA) disease [17,18], vasculitis (including ANCA-associated vasculitis, Wegener's granulomatosis and Behçet's disease) [19], chronic spontaneous autoreactive urticaria [20], and generalized vitiligo [21,22,23] have repeatedly been reported. PTPN22 polymorphisms also affect the responses of chronic-phase chronic myeloid leukemia patients to treatment with the tyrosine kinase inhibitor imatinib [24].…”